Mass spectrometry research aims for 1,000-fold improvement in pharma imaging technology
Imaging technology used by pharma firms could be more sensitive following research based on mass spectrometry

Bioanalytical

Mass spectrometry research aims for 1,000-fold improvement in pharma imaging technology

14 Jul, 2010

Published over 16 years ago. See the latest and most current information on Bioanalytical.

Research being conducted at Case Western Reserve University aims for a 1,000-fold enhancement of the mass spectrometry-based structural imaging technology used by pharma developers.

Dr Mark Chance, director of the university's school of medicine's Centre for Proteomics and Bioinformatics, explains that examining the structure of G-protein coupled receptors and similar membrane proteins is difficult.

However, pharma developers must determine how drugs are able to switch on and off those receptors if they are able to create therapeutics for diabetes, heart failure and depression.

Using mass spectrometry techniques, Dr Chance and his team succeeded in capturing a high-resolution image of the open state of a potassium channel, enabling analysis of gating mechanisms with applications in nerve signalling and heart function.

The 1,000-fold enhancement in imaging is one of the primary aims of the group led by Dr Chance, whose research focuses on the potential of structural genomics initiatives made possible by high-throughput analysis.

Latest News

Explore Our Other Sites

Labmate Online
Single medium supports both 2D and 3D pluripotent stem cell culture and growth
Explore more Arrow
Envirotech Online
Peristaltic pumps for high-purity oxygen applications
Explore more Arrow
Pollution Solutions Online
Vacuum technology enables efficient lithium-ion battery recycling with recovery rates of up to 95%
Explore more Arrow
Petro Online
The expanding role of high-temperature, high-shear viscometry in modern engine oil development
Explore more Arrow